Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Change in Accured Expenses data on file, last reported at $4.3 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $4.3 million, up 908.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $136.7 million (up 328.67% YoY), and the FY2025 annual result was $131.9 million, up 279.96% from the prior year.
• Change in Accured Expenses grew to $4.3 million in Q1 2026 per MDGL's latest filing, from -$88.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $187.5 million in Q3 2025 and troughed at -$88.4 million in Q4 2025.
• A 5-year average of $12.1 million and a median of $4.3 million in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses jumped 1712.96% in 2024, then tumbled 1301.7% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $11.9 million in 2022, then plunged by 37.87% to $7.4 million in 2023, then slumped by 185.59% to -$6.3 million in 2024, then plunged by 1301.7% to -$88.4 million in 2025, then surged by 104.85% to $4.3 million in 2026.
• Business Quant data shows MDGL's Change in Accured Expenses at $4.3 million in Q1 2026, -$88.4 million in Q4 2025, and $187.5 million in Q3 2025.